ARRY-520, KSP(Eg5) inhibitor; intravenous

DRUG4 trials

Sponsors

Array Biopharma, now a wholly owned subsidiary of Pfizer, Pfizer

Conditions

Acute Myeloid LeukemiaAdvanced MDSAdvanced Solid TumorsMultiple MyelomaMultiple Myeloma, Plasma Cell LeukemiaPlasma Cell Leukemia

Phase 1

A Study of ARRY-520 in Patients With Advanced Cancer

CompletedNCT00462358

Array Biopharma, now a wholly owned subsidiary of PfizerAdvanced Solid Tumors

Start: 2007-04-30End: 2010-11-30Updated: 2020-09-28

A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

CompletedNCT00637052

PfizerAcute Myeloid Leukemia, Advanced MDS

Start: 2008-03-18End: 2010-06-21Updated: 2021-02-08

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT00821249

PfizerMultiple Myeloma, Plasma Cell Leukemia

Start: 2009-01-31End: 2016-03-16Updated: 2020-10-19

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

CompletedNCT01248923

Array Biopharma, now a wholly owned subsidiary of PfizerMultiple Myeloma, Plasma Cell Leukemia

Start: 2010-12-31Updated: 2020-09-30

Related Papers

A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

Cancer2017-08-1772 citations

A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.

2011-12-0247 citations